The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).
 
Shom Goel
Consulting or Advisory Role - Lilly; Pfizer
Speakers' Bureau - Novartis
Research Funding - G1 Therapeutics; Lilly
Travel, Accommodations, Expenses - Novartis
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Consulting or Advisory Role - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GRAIL; Ipsen; Jounce Therapeutics; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Antoinette R. Tan
Consulting or Advisory Role - Abbvie; Athenex; Celgene; Eisai; G1 Therapeutics; Genentech/Roche; immunomedics; Merck; Novartis
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence
 
Boris Milev Krastev
Consulting or Advisory Role - G1 Therapeutics
Research Funding - G1 Therapeutics
Travel, Accommodations, Expenses - ROCHE, Pfizer
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology
Consulting or Advisory Role - Samsung
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; Pfizer
 
Philippe Georges Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; G1 Therapeutics; Macrogenics; Novartis; Novartis; Radius Health; Roche; Servier
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium
 
Denise A. Yardley
Consulting or Advisory Role - Athenex (Inst); Biotheranostics (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); R-Pharm (Inst); Sanofi/Aventis (Inst)
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Biomarin (Inst); Biothera (Inst); Clovis Oncology (Inst); Dana Farber Cancer Hospital (Inst); Genentech/Roche (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); NSABP Foundation (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Polyphor (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Novartis
 
Andric Zoran
No Relationships to Disclose
 
Curt Douglas Wolfgang
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Jessica Sorrentino
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Wenli Tao
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Andrew Paul Beelen
Employment - Epizyme (I); G1 Therapeutics; In8Bio (I); Incyte (I)
Stock and Other Ownership Interests - Amarin Corporation; G1 Therapeutics
 
Rajesh K. Malik
Employment - G1 Therapeutics
Leadership - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Sarika Jain
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics